Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Grail finds the path for its liquid biopsy less clear than it might have hoped.
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.